Is sermorelin the same as HGH?

No. Human growth hormone (somatropin) is the hormone itself, injected directly. Sermorelin is a copy of the first 29 amino acids of growth-hormone-releasing hormone — the signal that asks your pituitary to release its own growth hormone. Your body's feedback loop stays in control of how much is released.

Is sermorelin FDA-approved?

The brand product Geref (sermorelin acetate) was FDA-approved in 1997 for a pediatric indication and was discontinued in 2008. FDA's records state it was not withdrawn for safety or effectiveness reasons. Today sermorelin is prepared by compounding pharmacies on a provider's prescription — and compounded medications are not FDA-approved as a category.

Will sermorelin build muscle or burn fat?

The honest answer is that the human trials are small and mixed. One six-week trial in older men found strength gains on some measures but no change in body composition or IGF-1. A 2003 review concluded the results do not yet support routine use in normal aging. It is a provider-evaluated therapy, not a shortcut.

Sermorelin: What It Is and How It Works

The one-sentence version

Sermorelin is a synthetic copy of the first 29 amino acids of growth-hormone-releasing hormone (GHRH) — the signal your hypothalamus sends to your pituitary gland to release growth hormone. It is not growth hormone. It is the request for it.

That distinction is the whole story, so let’s slow down on it.

How it works

Your body releases growth hormone in pulses, mostly at night, and the size of those pulses tends to decline with age. Sermorelin binds to the same pituitary receptors as your natural GHRH and prompts the gland to release its own growth hormone (Walker, Clinical Interventions in Aging, 2006).

Two consequences follow, and both are why clinicians distinguish sermorelin from injected growth hormone:

Your feedback loop stays in charge. Growth hormone release is held in check by somatostatin, the body’s “enough” signal. Because sermorelin works upstream of that brake, the author of the review above argues that “overdoses of endogenous hGH are difficult if not impossible to achieve” — unlike direct injection of the hormone itself.
Release stays pulsed, not constant. Pituitary output under sermorelin is “episodic or intermittent rather than constant as with injected rhGH,” which is closer to the body’s own pattern.

Those are mechanistic arguments, and they are reasonable ones. They are not the same as proof of a clinical benefit — which is the next section.

Regulatory status, plainly

Geref (sermorelin acetate, NDA 020443) was FDA-approved on September 26, 1997 for a pediatric growth indication. It is listed as discontinued; the Federal Register notice states the product “was not discontinued or withdrawn for safety or effectiveness” reasons (Drugs@FDA, NDA 020443).
Among the growth-hormone secretagogue class, FDA notes that “only sermorelin (Geref, NDA 020443) was approved” — for short stature associated with growth hormone deficiency in children — and that “no GHSs … have been approved for the treatment of either adult- or childhood-onset GHD in adults” (FDA PCAC briefing document, Oct 29 2024).
Today it is a compounded medication. Under section 503A, a compounding pharmacy may use a bulk substance that complies with a USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA’s 503A bulks list (FDA — bulk drug substances under 503A). Compounded sermorelin is prepared for a specific patient on a provider’s prescription, and compounded medications are not FDA-approved as a category.

If a seller tells you sermorelin is “FDA-approved for anti-aging,” that is not accurate. If a seller tells you it is banned, that is not accurate either.

What the human trials actually found

This is where most sermorelin marketing goes quiet, so here is the record as published:

Strength, not body composition (6 weeks, 11 men). Older men (64–76) self-injected GHRH 1-29 nightly for six weeks. Two strength measures and one endurance measure improved; weight, BMI, waist-to-hip ratio, DEXA body composition and IGF-1 did not change. “No significant adverse effects were observed” (Vittone et al., Metabolism, 1997).
Cognition (6 months, 89 adults). Daily GHRH in healthy older adults (mean age 68) improved performance IQ, attention and executive-function tasks, independent of sex or baseline ability (Vitiello et al., Neurobiology of Aging, 2006). A later 20-week controlled trial of a different, longer-acting GHRH analog (tesamorelin) in 152 adults also reported favorable effects on cognition (Baker et al., Archives of Neurology, 2012).
Sleep is mixed. GHRH enhanced non-REM sleep after sleep deprivation in one human study (Schüssler et al., 2006), while intravenous GHRH impaired sleep in healthy young women in another (Mathias et al., 2007). “Better sleep” is a common claim; the evidence does not support it as a promise.
The reviewers’ bottom line. A review of GHRH and secretagogues in normal aging found some cognitive improvement and increased lean mass across studies but concluded the results “do not yet support the routine use of GHRH or GHS in normal aging” (Merriam et al., Endocrine, 2003). A 2025 clinical review of growth hormone and aging reaches a similar place: growth hormone is “not advised for antiaging purposes in healthy older people,” and long-term safety for healthy aging “remain[s] uncertain” (Fernández-Garza et al., Frontiers in Aging, 2025).

Read together: small trials, short durations, some real signals (strength measures, cognition), no demonstrated fat loss, and no long-term outcome data. That is the honest state of the science, and it is why this is a provider-evaluated therapy rather than a product you add to a cart.

Safety: what to weigh with your provider

The six-week trial above reported no significant adverse effects. Longer and larger data specific to sermorelin in adults do not exist, so providers also weigh the known risks of raising growth-hormone activity in general — fluid retention, joint aches, carpal tunnel symptoms and effects on blood sugar are the ones the 2025 review catalogs for growth hormone itself (Fernández-Garza et al., 2025). Because growth hormone and IGF-1 drive cell growth, a history of cancer is a standard reason a provider will decline to prescribe. Injection-site reactions are the most common practical complaint with any subcutaneous peptide.

None of this is a reason to panic; it is the reason a licensed provider reviews your history and labs first.

What sermorelin is not

Not HGH. Growth hormone (somatropin) is the hormone itself; sermorelin is the upstream signal. We do not offer injected growth hormone.
Not a performance or physique product. We don’t market it that way, and the trials above don’t support that framing.
Not a diagnosis. Fatigue, poor sleep and slow recovery have many causes — thyroid, iron, sleep apnea, low testosterone, depression. A provider evaluation looks at those first.

How BioPeakRx handles it

Sermorelin is available only after a licensed provider evaluates you and determines it is clinically appropriate. It is prepared by a US, FDA-registered compounding pharmacy on that prescription, shipped to you, and billed as a monthly, cancel-anytime subscription with the price and renewal terms shown before you pay. Pricing and the full therapy page are at /treatments/sermorelin/.

Compounded medications are not FDA-approved. This article is education, not medical advice, and does not establish a provider–patient relationship.

Sources: Walker RF, Clin Interv Aging 2006 (PMC2699646) · Drugs@FDA — Geref NDA 020443 · FDA PCAC Briefing Document, Oct 29 2024 · FDA — Bulk Drug Substances Used in Compounding Under Section 503A (updated May 14 2026) · Vittone J et al., Metabolism 1997 (PMID 9005976) · Vitiello MV et al., Neurobiol Aging 2006 (PMID 16399214) · Baker LD et al., Arch Neurol 2012 (PMID 22869065) · Schüssler P et al., Am J Physiol Endocrinol Metab 2006 (PMID 16912060) · Mathias S et al., Psychoneuroendocrinology 2007 (PMID 17850984) · Merriam GR et al., Endocrine 2003 (PMID 14610297) · Fernández-Garza LE et al., Front Aging 2025 (PMC12009952)